Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
about
Advanced tracers in PET imaging of cardiovascular diseaseImpact of β-blocker selectivity on long-term outcomes in congestive heart failure patients with chronic obstructive pulmonary diseasePrediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and β blockers in patients with idiopathic dilated cardiomyopathy.Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at higAdaptive servo-ventilation therapy using an innovative ventilator for patients with chronic heart failure: a real-world, multicenter, retrospective, observational study (SAVIOR-R).Effect of beta-blocker therapy on functional status in patients with heart failure--a meta-analysis.Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a long-term special survey.Artist® tablets (carvedilol) for hypertensive patients in Japan: results of a drug use surveyChronic heart failure in Japan: implications of the CHART studies.Ryanodine receptor-mediated arrhythmias and sudden cardiac death.Effect of carvedilol on reduction in heart rate in patients with chronic atrial fibrillationβ-Blockers in heart failure: benefits of β-blockers according to varying male proportions of study patients.The Real Role of β-Blockers in Daily Cardiovascular Therapy.Carvedilol in chronic heart failure: past, present and future.Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach.Cardiopulmonary Exercise Testing in Patients with Chronic Heart Failure: Prognostic Comparison from Peak VO2 and VE/VCO2 Slope.Clinical trials update from the American Heart Association meeting 2009: HEAAL, FAIR-HF, J-CHF, HeartMate II, PACE and a meta-analysis of dose-ranging studies of beta-blockers in heart failure.The need for multicentre cardiovascular clinical trials in Asia.Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF).Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.Evaluation of global circumferential strain as prognostic marker after administration of β-blockers for dilated cardiomyopathy.Clinical significance of endomyocardial biopsy in conjunction with cardiac magnetic resonance imaging to predict left ventricular reverse remodeling in idiopathic dilated cardiomyopathy.Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary interventionMortality after admission for heart failure in the UK compared with Japan
P2860
Q27023690-A000FC54-791A-43D0-B190-70FD6C06A792Q35168749-1919E947-8BAE-47BC-8265-143B7F1A189BQ35224187-94693EFB-352C-48E5-99BD-C7F5EE5EEF9EQ36156912-79F6A1D7-5DC3-48FF-A6BE-32841554FD69Q36289860-138F179F-A52D-4318-9660-24FE8AE1F58AQ36352751-2A4ECC04-DE3E-40DD-A693-EC0B3F583F2EQ36648994-173D13A4-FDE1-476C-A06E-2EA4046BA6C7Q36650008-9102962E-73E2-4D4A-8D8B-0014BBB12301Q36766968-2D55151D-DB6D-4A4A-9DED-1B92F4D0A3A8Q37248371-3EEEC6F7-A325-4A31-8209-5851BD61CEFDQ37255221-2E0C878B-571C-4BBF-BBEA-4880C05C2FAAQ38001302-F46A17DE-BD55-4DFE-96D9-BF04448D7646Q39208428-C75F3A6F-2BF8-4DFF-8CB7-975F35EB0992Q40377169-3C7C8C33-2AE5-459C-B66E-96C676A5FD62Q41845098-74D201A6-805D-41B7-9F4B-621AE6B340F5Q42111594-104D2AE9-801B-4222-9AE1-4F9BE34F821FQ43190662-4CCD1670-A97A-42A9-87C4-F240FC2DAFE0Q43609145-709F3D9B-B20D-48D1-AA2F-4101F7BDE489Q45835594-0B399E4E-0CC3-46CD-9A21-FC92423306F3Q48818918-B322DCD6-1321-4945-9198-CC467FDF10B7Q50616320-EF8CB05B-965E-44C6-8F3A-5F1D8E392F00Q53162924-6D424523-639E-47C9-B2B1-90989FC8EF83Q58699927-2A49B59B-EC47-44C1-BFF7-783E6365A5E4Q58751286-C0176A7F-026F-4237-950B-FFFE0CEC17BC
P2860
Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Low-dose carvedilol improves l ...... Dose Assessment (MUCHA) trial.
@en
Low-dose carvedilol improves l ...... Heart Failure Dose Assessment
@nl
type
label
Low-dose carvedilol improves l ...... Dose Assessment (MUCHA) trial.
@en
Low-dose carvedilol improves l ...... Heart Failure Dose Assessment
@nl
prefLabel
Low-dose carvedilol improves l ...... Dose Assessment (MUCHA) trial.
@en
Low-dose carvedilol improves l ...... Heart Failure Dose Assessment
@nl
P2093
P921
P1476
Low-dose carvedilol improves l ...... Dose Assessment (MUCHA) trial.
@en
P2093
Akira Kitabatake
Akira Takeshita
Hideki Origasa
Kennichi Matsui
MUCHA Investigators
Masatsugu Hori
Masunori Matsuzaki
Mitsuhiro Yokoyama
Saichi Hosoda
Shigetake Sasayama
P304
P356
10.1016/J.AHJ.2003.07.023
P407
P577
2004-02-01T00:00:00Z